Anika Responds to CINGAL’s Drug Classification

In late 2015, FDA assigned Anika Therapeutics’ CINGAL® to the Center for Drug Evaluation and Research (CDER) and not the Center for Devices and Radiological Health (CDRH) for its premarket review—a decision with which Anika’s leadership says it disagrees.

CINGAL is the first combination viscosupplement formulated with Anika’s cross-linked...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Carolyn LaWell is ORTHOWORLD's Chief Content Officer. She joined ORTHOWORLD in 2012 to oversee its editorial and industry education. She previously served in editor roles at B2B magazines and newspapers.

Contact Us